[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
Status:
Unknown status
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
Regorafenib is approved in the treatment for metastatic colorectal cancer patients who have
been progressed after standard therapies, however, there has not been a predictive biomarker.
The investigators designed this study to investigate whether [18F]FLT-PET might paly a role
as a predictive imaging biomarker of treatment responses to regorafenib.